Tvm-Capital

TVM Capital Life Science invests in the development of exciting life science products and the growth of companies to become innovative leaders in their market segment. They work closely with portfolio companies as true partners, enabling their ideas and bringing new therapies and medical products to market. Their approach focuses on building value for investors by providing capital to reach value inflection points, offering solid exit options. TVM employs a dual-pronged strategy. One aspect involves financing innovative early-stage therapeutics through single-asset companies, leveraging a strategic relationship with Eli Lilly and Company. The other is investing in differentiated commercial-stage medtech, diagnostics, digital health products, and late-stage therapeutics. TVM focuses on investments with clear and attractive exit strategies to maximize returns in a reasonable timeframe. Beyond capital, TVM provides portfolio companies with resources tailored to their needs, including recruiting management and board members, honing development, sales and marketing plans, QMS and manufacturing/supply chain logistics, regulatory strategies, finding potential partners, and executing financing and exit strategies. They aim to build groundbreaking companies that become industry leaders. TVM Capital Life Science emerged from Techno Venture Management, launched in 1983, and has focused exclusively on Life Sciences since 2012. The firm invests in assets and companies that provide a clear and attractive exit strategy, with the goal of maximizing returns.